MorphoSys AG buy mohabbatein
Summary
This prediction ended on 22.03.17 with a price of €53.85. The prediction had a final performance of 24.26%. mohabbatein has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 0.371% | 0.371% | 123.915% | 23.448% |
| iShares Core DAX® | -0.612% | 0.567% | 12.585% | 14.838% |
| iShares Nasdaq 100 | -3.018% | -3.205% | 26.208% | 38.328% |
| iShares Nikkei 225® | -2.647% | 0.330% | 9.482% | 5.652% |
| iShares S&P 500 | -1.932% | -1.126% | 23.191% | 38.791% |
Comments by mohabbatein for this prediction
In the thread Morphosys AG diskutieren
mohabbatein stimmt dem Crowdsentiment von 'Buy' zu
mohabbatein stimmt am 07.10.2016 dem Buy-Crowdsentiment mit dem Kursziel 59.16€ zu.
Endlich gibt es von Morphosys wieder positive Nachrichten. Das erste Medikament, das auf Morphosys-Technologie aufbaut, steht nach sehr positiven Forschungsdaten nun kurz vor der Zulassung. Guselkumab könnte die Wende zum besseren für die Münchner bringen. Die Analystengilde stuft schon mal fröhlich hoch.
BUY.